RYOAX Performance — Biotechnology Fund, Class H
Data updated: 2026-08-28
RYOAX returned +19.26% year to date and +58.05% over one year to Jun 2026. Annualised returns are +18.55% over 3 years and +5.80% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $167, against $138 for the category, and to $158 over one year, against $137. Volatility over the past three years was 17.12% a year. In the 12 months to Jun 2026 the fund took in a net $19.6M, and assets reached $136.81M.
RYOAX Growth of $100
What $100 invested in Biotechnology Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | RYOAX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $158 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $167 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $133 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $191 | $182 |
RYOAX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +19.26% |
| 1 year | +58.05% |
| 3 years (annualised) | +18.55% |
| 5 years (annualised) | +5.80% |
RYOAX Annual Returns
Calendar-year total returns of Biotechnology Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +19.26% |
| 2025 | +30.42% |
| 2024 | −0.98% |
| 2023 | +5.80% |
| 2022 | −13.28% |
| 2021 | +1.56% |
| 2020 | +21.78% |
| 2019 (Jul–Dec) | +9.40% |
RYOAX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.1% | +2.2% | −2.3% | +1.0% | +4.7% | +10.7% | — | — | — | — | — | — |
| 2025 | +5.4% | −0.3% | −6.2% | +0.3% | −3.6% | +3.2% | +4.1% | +4.9% | +5.4% | +8.8% | +8.1% | −2.1% |
| 2024 | −1.3% | +2.2% | −0.1% | −7.3% | +5.2% | +4.6% | +6.0% | +1.7% | −2.8% | −1.5% | +1.1% | −7.8% |
| 2023 | +2.2% | −4.5% | +0.1% | +1.8% | −2.6% | +0.9% | +0.9% | −0.5% | −4.3% | −6.1% | +6.2% | +13.0% |
| 2022 | −10.5% | −3.1% | +3.9% | −10.0% | −0.3% | 0.0% | +5.2% | −3.6% | −3.5% | +7.8% | +6.4% | −4.3% |
| 2021 | +5.3% | −2.2% | −4.4% | +4.3% | −3.4% | +9.2% | −1.6% | +3.7% | −5.2% | +0.2% | −4.5% | +1.3% |
| 2020 | −7.4% | 0.0% | −7.8% | +15.9% | +9.0% | +1.5% | +0.3% | −0.3% | +0.4% | −2.7% | +10.5% | +3.1% |
| 2019 | — | — | — | — | — | — | −3.4% | −3.8% | −1.6% | +6.8% | +12.2% | −0.2% |
RYOAX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 17.12%
- 3-year Sharpe ratio: 0.82 (vs 4.5% risk-free rate)
- Best month: +12.96% (Dec 2023)
- Worst month: −7.76% (Dec 2024)
RYOAX Fund Flows
Monthly money in and out of Biotechnology Fund, from SEC Form N-PORT.
- 12-month net flow: $19.6M
- 12-month gross sales (incl. reinvestments): $105.6M
- Sales ÷ redemptions: 1.23×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $20.8M | $11.5M | $9.3M |
| May 2026 | $7.4M | $5.4M | $2.0M |
| Apr 2026 | $3.7M | $31.8M | −$28.1M |
| Mar 2026 | $1.1M | $1.2M | −$189K |
| Feb 2026 | $1.7M | $2.5M | −$772K |
| Jan 2026 | $29.1M | $4.3M | $24.8M |
| Dec 2025 | $19.7M | $13.0M | $6.7M |
| Nov 2025 | $10.5M | $1.5M | $9.0M |
| Oct 2025 | $5.0M | $3.1M | $1.9M |
| Sep 2025 | $338K | $2.3M | −$2.0M |
| Aug 2025 | $2.7M | $4.1M | −$1.3M |
| Jul 2025 | $3.6M | $5.3M | −$1.7M |
RYOAX Assets Under Management
Net assets of Biotechnology Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $136.81M |
| 2026-03-31 | $135.07M |
| 2025-12-31 | $109.00M |
| 2025-09-30 | $90.01M |
| 2025-06-30 | $82.73M |
| 2025-03-31 | $87.25M |
| 2024-12-31 | $91.71M |
| 2024-09-30 | $111.15M |
| 2024-06-30 | $109.35M |
| 2024-03-31 | $109.62M |
| 2023-12-31 | $112.45M |
| 2023-09-30 | $104.44M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.